OVERVIEW
Ampyra is a potassium channel blocker that is indicated to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The recommended maximum dose is 10 mg twice daily (BID) given approximately 12 hours apart. No additional benefits were noted when given at doses greater than 10 mg BID and adverse events (AEs), including seizures, were more common at higher doses. The tablets should be taken whole and not divided, crushed, chewed or dissolved. Ampyra is contraindicated in patients with a history of seizures; moderate or severe renal impairment (estimated creatinine clearance [CrCl] ≤ 50 mL/min); and in those with a history of hypersensitivity to Ampyra or 4-aminopyridine.

POLICY STATEMENT
Prior authorization is recommended for prescription benefit coverage of Ampyra. Because of the specialized skills required for evaluation and diagnosis of patients treated with Ampyra as well as the monitoring required for AEs and long-term efficacy, approval requires Ampyra to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Coverage of Ampyra is recommended in those who meet the following criteria:

1. **Multiple Sclerosis (MS).** Approve if the patient meets the following criteria (a, b, c, d, e, and f):
   a) Objectively assessed for functional impairment related to ambulation and there is documentation of such impairment in the patient’s chart; AND
   b) Ampyra is being prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of MS; AND
   c) The dose of Ampyra will not exceed 10 mg twice daily; AND
   d) No history of seizures; AND
   e) No moderate to severe renal impairment (CrCl≤50 mL/min); AND
   f) No history of sensitivity to Ampyra or 4-aminopyridine.

2. **Patient has been started on Ampyra (re-authorization).** Approve if there is documentation that the patient has experienced sustained and clinically meaningful improvement in walking speed (e.g. as observed by examination by the physician using the timed 25-foot walk test)

**Approval Duration**
Initial Approval = 4 months
Extended Approval (re-authorization) = 365 days (1 year)
REFERENCES